Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET)

Barry M. Massie, Martin R. Berk, Susan C. Brozena, Uri Elkayam, Jonathan F. Plehn, Marrick L. Kukin, Milton Packer, Bruce E. Murphy, Gerald W. Neuberg, Richard M. Steingart, T. Barry Levine, Hans DeHaan

Clinical Sciences

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET)

Fingerprint

Medicine & Life Sciences